STAT+: Pharmalittle: We’re reading about a U.S. senator probing FDA, BioNTech founders leaving, and much more

Story Timeline

1. 2026-02-23
   STAT+: Pharmalittle: We’re reading about pharma lobbying, a disappointing Novo clinical trial, and much more (Stat News)
2. 2026-02-24
   STAT+: Pharmalittle: We’re reading about an FDA plan for ultra-rare drugs, Novo cutting GLP-1 drug prices, and more (Stat News)
3. 2026-02-25
   STAT+: Pharmalittle: We’re reading about Trump’s drug-price claims, a Novo deal for obesity drugs, and more (Stat News)+1 more source
4. 2026-02-26
   STAT+: Rare disease advocates fume over FDA’s mixed signals (Stat News)+1 more source
5. 2026-03-02
   STAT+: Pharmalittle: We’re reading about Trump’s MFN deals, 340B program controversies, and much more (Stat News)
6. 2026-03-09
   STAT+: As controversial decisions mount, FDA shuns public advisory meetings (Stat News)+1 more source
7. 2026-03-10
   STAT+: Pharmalittle: We’re reading about a U.S. senator probing FDA, BioNTech founders leaving, and much more (current)

   +1 more source

Score BreakdownRisk 65

Stories gain Lindy status through source reputation, network consensus, and time survival.